The litigation centers on disclosures made on May 4, 2026, when GeneDx reported a decline in adjusted gross margins from 74% to 69%. The company missed revenue targets for its exome and genome product lines, subsequently slashing its full-year revenue guidance to a range of $475 million to $490 million, down from an earlier projection of $540 million to $550 million.
GeneDx Investors Face August Deadline in Securities Class Action
Investors who lost more than $100,000 in GeneDx Holdings Corp. stock between April 2025 and May 2026 have until August 3, 2026, to file lead plaintiff applications. The lawsuit, pending in the U.S. District Court for the District of Connecticut, alleges the company failed to disclose critical financial vulnerabilities.
Central to the complaint is a $31.2 million impairment loss tied to the acquisition of Fabric Genomics. While GeneDx previously marketed the AI-driven firm as a transformative engine for recurring revenue, the market reaction to these combined financial setbacks was severe, triggering a 49.2% drop in share price—a decline of $33.42 per share. ClaimsFiler is currently coordinating legal outreach for affected shareholders through the firm Kahn Swick & Foti, LLC.
Comments (0)
No comments yet. Be the first!